Caroline van der Meijden appointed as Interim Director of iMTA
We are pleased to announce that Caroline van der Meijden will join iMTA as Interim Director starting May 1st, 2025. In this role, Caroline will be responsible for business development and she will be the key contact person for both existing and new clients. Daily management will remain in the capable hands of Martine Hoogendoorn-Lips, while Carin Uyl-de Groot and Maureen Rutten-van Mölken will continue to provide scientific leadership and advice.
Caroline brings a wealth of experience to iMTA. Most recently, she has been Director at Valence Consultancy, where she advised pharmaceutical and biotech companies on reimbursement strategies, study design, and health policy. She has also served as an expert evaluator for government procedures and worked closely with patient organizations. Her prior roles include leadership positions in market access and health economics at several pharmaceutical companies, where she was involved in achieving reimbursement for innovative medical products across Europe. Caroline also brings valuable experience from her time at the Dutch Health Care Institute (ZIN), where she was responsible for the assessment of pharmacotherapeutic value and cost-effectiveness.
We are very glad to welcome Caroline to iMTA and look forward to the insights and energy she will bring to the team.
Get in touch with Caroline HERE.
